Back to today’s briefing

Story perspectives

Biogen and Stoke Partner on $165M Dravet Treatment

2/18/2025

46 4

Summary

Story summary

Biogen and Stoke Therapeutics are joining forces to advance zorevunersen, an experimental treatment for Dravet syndrome, beyond U.S. borders. This strategic partnership grants Stoke an impressive $165 million upfront for a Phase 3 study, with the potential for an additional $385 million. Biogen is focused on revitalizing its rare disease pipeline and driving growth.

1 of 1

Story summary

Biogen and Stoke Therapeutics are joining forces to advance zorevunersen, an experimental treatment for Dravet syndrome, beyond U.S. borders. This strategic partnership grants Stoke an impressive $165 million upfront for a Phase 3 study, with the potential for an additional $385 million. Biogen is focused on revitalizing its rare disease pipeline and driving growth.